<DOC>
	<DOC>NCT00143091</DOC>
	<brief_summary>A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.</brief_summary>
	<brief_title>Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder</brief_title>
	<detailed_description>This study was terminated on March 17th, 2006. The results of the primary analysis at the interim showed that the CP-316,311 group was not significantly different than the placebo on the primary endpoint and therefore the data monitoring committee recommended termination of the trial. The decision to terminate the trial was not based on any safety concerns.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Outpatients with DSMIV major depressive disorder Women of child bearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Major Depressive Disorder, Recurrent</keyword>
</DOC>